imatinib mesylate has been researched along with Myofibromatosis in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, A; Blanding, D; Boulouadnine, B; Demoulin, JB; Elsbernd, A; Farooqi, M; Sandritter, T; Shakhnovich, V; Thompson, J | 1 |
| Clauditz, T; Königs, I; Kordes, U; Reinshagen, K; Schubert, JP; Wößmann, W | 1 |
| Arndt, C; Bidadi, B; Kirkham, J; Oliveira, A; Watson, A; Weigel, B | 1 |
| Adam, MP; Albert, CM; Amiel, J; Beck, AE; Bhoj, EJ; Bly, RA; Boos, MD; Chang, I; Chenbhanich, J; Christodoulou, J; Curry, C; Dahl, JP; Dobyns, WB; Everman, D; Ganapathi, S; Guimier, A; Gupta, D; Hakonarson, H; Heike, CL; Li, D; Miller, DE; Park, J; Perkins, JA; Shieh, J; Sun, A; Webster, R; Wenger, TL; Wilson, M; Wu, N; Zackai, EH; Zarate, YA | 1 |
| Agaimy, A; Bourdeaut, F; Dachy, G; de Krijger, RR; Demoulin, JB; Duncan, C; Hettmer, S; Hirsch, S; Jongmans, M; Kordes, U; Kratz, CP; Kventsel, I; Metzler, M; Michaeli, O; Nemes, K; Poluha, A; Ripperger, T; Russo, A; Seitz, G; Smetsers, S; Sparber-Sauer, M; Stutz, E | 1 |
| Benchimol, G; Bodemer, C; Fraitag, S; Giacobbi, V; Orbach, D; Pierron, G; Proust, S; Starck, J | 1 |
| Bredrup, C; Bruland, O; Cristea, I; Houge, G; Høvding, G; Lee, S; McGaughran, J; Rødahl, E; Sapkota, D; Steen, VM; Stokowy, T; Tveit, KS; Xu, L | 1 |
| Gielen, GH; Herrlinger, U; Keil, VC; Schäfer, N; Weller, JM | 1 |
| Arts, FA; Chand, D; Constantinescu, S; Demoulin, JB; Hallberg, B; Pecquet, C; Velghe, AI | 1 |
9 other study(ies) available for imatinib mesylate and Myofibromatosis
| Article | Year |
|---|---|
Novel Oncogenic
Topics: Carcinogenesis; Drug Monitoring; Humans; Imatinib Mesylate; Myofibromatosis; Receptor, Platelet-Derived Growth Factor beta | 2022 |
Generalized Infantile Myofibromatosis with Extensive Small Bowel Involvement in a Neonate.
Topics: Child; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Male; Myofibromatosis | 2023 |
Treatment of generalized infantile myofibromatosis with sorafenib and imatinib: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Imatinib Mesylate; Infant; Myofibromatosis; Prognosis; Sorafenib | 2020 |
Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy.
Topics: Adolescent; Adult; Aneurysm; Child; Female; Genetic Association Studies; Humans; Imatinib Mesylate; Infant; Leukoencephalopathies; Male; Myofibromatosis; Pedigree; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta | 2020 |
Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group.
Topics: Child; Child, Preschool; Genetic Testing; Humans; Imatinib Mesylate; Myofibromatosis; Receptor, Platelet-Derived Growth Factor beta | 2021 |
Major response to imatinib and chemotherapy in a newborn patient prenatally diagnosed with generalized infantile myofibromatosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Imatinib Mesylate; Infant, Newborn; Male; Methotrexate; Myofibromatosis; Prognosis; Vinblastine | 2021 |
A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome.
Topics: Acro-Osteolysis; Adult; Aging; Apoptosis; Cockayne Syndrome; Female; Genetic Predisposition to Disease; HeLa Cells; Humans; Imatinib Mesylate; Limb Deformities, Congenital; Male; Mitogen-Activated Protein Kinase 3; Mutation, Missense; Myofibromatosis; Phenotype; Phosphorylation; Progeria; Protein Interaction Maps; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction | 2019 |
PDGRFB mutation-associated myofibromatosis: Response to targeted therapy with imatinib.
Topics: Adult; Disease Progression; Genetic Predisposition to Disease; Heterozygote; Humans; Imatinib Mesylate; Male; Mutation; Myofibromatosis; Receptor, Platelet-Derived Growth Factor beta | 2019 |
PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.
Topics: Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Female; Growth Disorders; Humans; Imatinib Mesylate; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Knockout; Mutagenesis, Site-Directed; Mutation; Myofibromatosis; Neoplasms, Experimental; NIH 3T3 Cells; Oncogenes; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Syndrome | 2016 |